Helus Pharma reports news on clinical-stage pharmaceutical development for novel serotonergic agonists in mental health. Recurring updates cover HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, clinical and regulatory disclosures, research collaborations, and medical or scientific leadership.
Company news also includes governance changes, executive and advisory appointments, shareholder voting matters, capital-structure disclosure, operating and financial results, and participation in healthcare and life-sciences forums tied to the company's depression and anxiety pipeline.
Helus Pharma (Nasdaq: HELP) announced a collaboration with TARA Mind to support recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder and expand veteran mental health outreach. The program is described as FDA Breakthrough Therapy-designated, and the partnership aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness.
The release is a correction removing prior references to Veterans Exploring Treatment Solutions and emphasizes veteran-focused engagement and patient-centric clinical development.
Helus Pharma (Nasdaq: HELP) announced that Eric So, Interim Chief Executive Officer, will speak on a panel titled “The Next Wave of Health Innovation” at the 29th Annual Milken Institute Global Conference on May 4, 2026 at 2:30 p.m. PDT.
The conference runs May 3–6, 2026 in Los Angeles; the live panel and archived webcast will be available on the company’s Events & Presentations investor relations page.
Helus Pharma (Nasdaq: HELP) announced a collaboration with TARA Mind and Veterans Exploring Treatment Solutions (VETS) to support recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder and to expand veteran mental health outreach. The program holds FDA Breakthrough Therapy designation for HLP003. The partnership aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness and aims to increase veteran participation in clinical research and access to emerging therapeutic options.
Helus Pharma (Nasdaq: HELP) announced on April 23, 2026 the additions of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board.
The company said the appointments strengthen clinical and translational expertise as Helus advances novel serotonergic agonists, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder.
Helus Pharma (Nasdaq: HELP) welcomed a White House Executive Order on April 20, 2026, designed to accelerate research, regulatory review, and patient access for psychedelic therapies.
The company noted its lead candidate, HLP003, is in Phase 3 and has FDA Breakthrough Therapy designation for adjunctive major depressive disorder; Helus said it will continue late-stage development and regulatory engagement.
Helus Pharma (Nasdaq: HELP) announced a management change on April 20, 2026: CEO Michael Cola stepped down effective immediately and Co-founder and Executive Chairman Eric So will resume as Interim CEO while the Board conducts a search for a permanent successor.
The company said priorities remain advancing the clinical pipeline, including the APPROACH trial topline readout for HLP003 expected in the fourth quarter, and ensuring continuity of leadership during the transition.
Helus Pharma (Nasdaq: HELP) appointed Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs effective April 16, 2026. Dr. Kramer brings 25 years of neuroscience medical affairs experience, prior roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie, and leadership on a recent schizophrenia product launch.
This hire aims to scale medical capabilities, deepen clinician and payor engagement, and support advancement of Helus's serotonergic agonist pipeline.
Helus Pharma (Nasdaq: HELP) announced the appointment of Jill Conwell as Chief People Officer, effective March 12, 2026.
Conwell brings more than two decades of life‑science leadership, including roles at Aclaris, Idera, and Shire, and will support talent, organizational scaling, and culture as Helus advances its clinical serotonergic agonist pipeline.
Helus Pharma (Nasdaq: HELP) reported topline Phase 2 signal detection results for HLP004 in adults with moderate-to-severe generalized anxiety disorder on standard-of-care therapy. Patients given 20 mg showed a mean 10.4-point HAM-A reduction at six weeks (p<0.0001), with 67% responders and 39% remitters at six months. The randomized 36-patient study (2:1 active:placebo) found acute effects lasting ~90 minutes and discharge readiness within ~3 hours, and noted no drug-related serious adverse events.
Helus Pharma (Nasdaq: HELP) appointed Dr. Freda Lewis-Hall to its Board of Directors and named her Chair of the Scientific Advisory Committee, effective Feb 24, 2026. Dr. Lewis-Hall brings 40+ years in psychiatry and industry leadership, including over a decade as Pfizer chief medical officer and global regulatory experience.
She will guide clinical development, regulatory engagement, and scientific governance across Helus’ novel serotonergic agonist portfolio; appointment is subject to Cboe Canada approval.